Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

    Home > Events > Medtech__pharma_platform 2022

    1 min read

    Medtech & Pharma Platform (MPP) Conference 2022

     

    Veristat and SFL, a Veristat company,  will attend the Medtech & Pharma Platform 9th annual conference on 8 September 2022 in  Basel, Switzerland.

     

    Atalah Haun,  Veristat Senior Director- Medical Affairs, will speak in a panel presentation on Combined Products: Regulation & Patient Engagement in session 1 of the program.

     

    The session will provide various perspectives on outstanding challenges how to bridge the gap between the medicinal products and the medical devices frameworks. In the area of combined products, collaboration between the different stakeholders is key and, as such, the session will also address this topic by exploring patient engagement.

     

    Veristat and SFL, a Veristat company,  offer solutions that can further empower your team. Featured solutions include strategic and operational support from early development to regulatory approval, market access, quality assurance, pharmacovigilance, and supply chain management, as well as clinical development services including global clinical operations, biostatistics and programming.

     

    Schedule A Meeting

    If you would like to meet us at the Medtech & Pharma Platform conference , feel free to contact us to arrange a meeting through the form. 

     

     

    Medtech & Pharma Platform

     

     

     

    Conference Details

    Website:   Medtech & Pharma Platform 9th Annual Conference

     

     

    Share This Event:

       

    11 min read

    Monthly FDA Guidance and Regulatory News Review - September 2026

    This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...

    8 min read

    Monthly FDA Guidance and Regulatory News Review - August 2026

    This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...